Johnson & Johnson's Janssen Biotech Inc. is showing interest in stem cell therapy delivered to the heart via a catheter. Janssen is providing an upfront payment of $12.5 million related to Capricor Therapeutics Inc.'s CAP-1002 therapy ...
Tags: Janssen, Catheter, Stem Cell Tech